Progresses in DNA-based heterologous prime-boost immunization strategies.
Although recombinant DNA and recombinant viral vectors expressing HIV antigens have yielded positive outcomes in animal models, these vaccines have not been effectively translated to humans. Despite this, there is still a high level of optimism that poxviral-based vaccine strategies could offer the best hope for developing an effective vaccine against not only HIV-1 but also other chronic diseases where good-quality T and B cell immunity is needed for protection. In this chapter we discuss step by step (1) how recombinant poxviral vectors co-expressing HIV antigens and promising mucosal/systemic adjuvants (e.g., IL-13Rα2) are constructed, (2) how these vectors can be used in alternative heterologous prime-boost immunization strategies, (3) how systemic and mucosal samples are prepared for analysis, followed by (4) two immunological assays: multicolor intracellular cytokine staining and tetramer/homing maker analysis that are used to evaluate effective systemic and mucosal T cell immunity.
Molecular Mucosal Vaccine Immunology group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, 2601, Australia.
Ronald J
RJ
Jackson
David B
DB
Boyle
Charani
C
Ranasinghe
D000818:Animals; D018929:Cell Culture Techniques; D002642:Chick Embryo; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D051379:Mice; D011212:Poxviridae / Q000235:genetics / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology
D019444:Vaccines, DNA